2invest AG

Latest Results (04.09.2026):

2invest AG — results for Q4 2020 (financial year 2020): the company reported a strong year driven by the disposal of its proteomics & immunology business, posting a net profit of EUR 55.0m for FY2020 (versus a net loss of EUR 32.8m in 2019), materially higher cash and liquid securities, and a strategic transformation into an investment company following a spin‑off completed in December 2020.

Net profit (FY2020)

Net profit: EUR 55.033m in 2020, versus a net loss of EUR 32.832m in 2019 — the swing is mainly attributable to a net gain of EUR 68.4m from the Abcam transaction.

Cash, securities and escrow

Liquidity: cash and bank balances EUR 47.176m, listed securities EUR 19.147m (short‑term holding), and escrow cash claims EUR 14.4m (held as warranty/security for the Abcam sale, expected release 01‑Jan‑2022).

Balance sheet and equity

Total assets rose to EUR 85.565m (31‑Dec‑2020) from EUR 53.279m a year earlier; equity increased to EUR 84.501m (≈99% of the balance sheet).

Major transactions

Abcam Transaction: sale of proteomics & immunology businesses (effective 01‑Jan‑2020) produced the principal one‑off gain. Spin‑off: shares in the genomics/DNA units were spun off to 4basebio UK Societas (spin‑off effective on registration 08‑Dec‑2020).

Strategic change

Following the disposals and spin‑off, 2invest AG repositioned as an investment company focused on investing the cash proceeds (notably in listed securities), with a new name and business purpose approved by shareholders (name change effective early 2021).

Operating items and one‑offs

Other operating income: EUR 68.354m (mainly Abcam gain). Restructuring/extraordinary charges related to the spin‑off about EUR 9.7m. Operating revenue remained negligible (≈EUR 0.07m). Financial result was negative EUR 1.248m (interest and similar expenses).

Cash flow

Cash flow highlights: large investing cash inflow of EUR +63.8m (mainly sale proceeds), operating cash outflow of EUR −7.8m (one‑off restructuring and settlements), financing cash outflow of EUR −8.9m (including share buybacks).

Corporate actions & governance

Share capital consolidation and reduction (9:1) and several supervisory/management board changes were approved around year‑end/early 2021. The 2020 annual financial statements and management report were audited by Ernst & Young with an unqualified opinion.